NICOLETTE QUINN News & Analysis

And Morningstar analyst Nicolette Quinn has tempered her forecasts for sales of immunoglobulins.

It’s the leader in medical device disinfection but patent expiry and the potential for copycats raise doubts, says Nicolette Quinn. 

Respiratory specialist Fisher & Paykel Healthcare is among stocks now enticingly priced as the coronavirus hits markets and the Aussie dollar.

Quality companies hold a distinct advantage as they navigate the corona crisis but the sector at large remains resilient in the medium term, says...

The corona sell-off has unearthed discounts among makers of gloves, pharmaceutical goods and spray-on skin technology.